Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Type I Versus Type II Endometrial Cancer: Differential Impact of Comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jennifer J Mueller
  • Henrik Lajer
  • Berit Jul Mosgaard
  • Slim Bach Hamba
  • Philippe Morice
  • Sebastien Gouy
  • Yaser Hussein
  • Robert A Soslow
  • Brooke A Schlappe
  • Qin C Zhou
  • Alexia Iasonos
  • Claus Høgdall
  • Alexandra Leary
  • Roisin E O'Cearbhaill
  • Nadeem R Abu-Rustum
View graph of relations

OBJECTIVE: We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes.

METHODS: This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed.

RESULTS: Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy-55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery.

CONCLUSIONS: Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

Original languageEnglish
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume28
Issue number5
Pages (from-to)915-924
Number of pages10
ISSN1048-891X
DOIs
Publication statusPublished - Jun 2018

ID: 55852516